Galmed Pharmaceuticals (GLMD) Net Cash Flow (2013 - 2025)

Galmed Pharmaceuticals' Net Cash Flow history runs 13 years deep, the most recent figure standing at $671000.0 for Q4 2025.

• In Q4 2025, Net Cash Flow rose 113.4% year-over-year to $671000.0; the TTM figure through Dec 2025 stood at -$664000.0 (up 89.85% YoY), while the FY2025 annual figure was -$664000.0, down 136.99% from the prior year.
• Net Cash Flow was $671000.0 for Q4 2025 at Galmed Pharmaceuticals, up from -$1.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $6.4 million in Q1 2021 to a low of -$7.0 million in Q2 2022.
• Historically, Net Cash Flow has averaged -$861950.0 across 5 years, with a median of -$558000.0 in 2021.
• The sharpest annual moves came in 2021 and 2024: Net Cash Flow jumped 346.29% in 2021, then sank 553.27% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$605000.0 in 2021, then tumbled by 238.02% to -$2.0 million in 2022, then soared by 167.53% to $1.4 million in 2023, then plunged by 462.71% to -$5.0 million in 2024, then jumped by 113.4% to $671000.0 in 2025.
• The last three Net Cash Flow figures came in at $671000.0 (Q4 2025), -$1.6 million (Q3 2025), and $198000.0 (Q2 2025), per Business Quant data.